You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Details for Patent: 5,886,034


✉ Email this page to a colleague

« Back to Dashboard


Title: Prostaglandins E and anti ulcers containing same
Abstract:The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13, 14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.
Inventor(s): Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Nishinomiya, JP), Kato; Ichie (Kawanishi, JP), Oda; Tomio (Sanda, JP)
Assignee: Kabushiki Kaisha Ueno Seiyaku Kenkyujo (Osaka-Fu, JP)
Filing Date:Mar 10, 1995
Application Number:08/401,675
Claims:1. Prostaglandin E of general formula I:

wherein X is ##STR48## R.sub.1 is a hydrogen atom, a physiology acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;

R.sub.2 is a hydrogen atom or a methyl group;

R.sub.3 is a hydroxyl or hydroxymethyl group;

R.sub.4 is a hydrogen atom;

R.sub.5 is a hydrogen atom; and

R.sub.6 is a C.sub.6 -C.sub.9 straight alkyl group which may have a double bond,

wherein the C.sub.2 -C.sub.3 bond is a single bond.

2. The prostaglandin E of claim 1, wherein R.sub.6 is a C.sub.6 straight alkyl group.

3. The prostaglandin E of claim 1, wherein the general formula is. ##STR49##

4. The prostaglandin E of claim 1, which is 13,14-dihydro-15-keto-20-ethyl-PGE.sub.2 or alkyl ester thereof.

5. An anti-ulcer composition comprising an anti-ulcer effective amount of prostaglandin E of general formula I: ##STR50## wherein X is ##STR51## R.sub.1 is a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;

R.sub.2 is a hydrogen atom or a methyl group;

R.sub.3 is a hydroxyl or hydroxymethyl group;

R.sub.4 is a hydrogen atom;

R.sub.5 is a hydrogen atom; and

R.sub.6 is a C.sub.6 -C.sub.9 straight alkyl group which may have a double bond,

wherein the C.sub.2 -C.sub.3 bond is a single bond.

6. The anti-ulcer composition of claim 5, wherein R.sub.6 is a C.sub.6 straight alkyl group.

7. The anti-ulcer composition as described in claim 5, wherein the general formula is. ##STR52##

8. The anti-ulcer composition of claim 5, which is 13,14-dihydro-15-keto-20-ethyl-PGE.sub.2 or alkyl ester thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.